Milestone & Recognitions
2022
- GBC completes Covid-19 indication Phase 2 trial development.
- GBC obtains IND approval of Antroquinonol for AML indication from US FDA.
2021
- Covid-19 Drug Dual Achievements: GBC’s new drug Antroquinonol (HOCENA) trial receives positive response from DMC review and licenses for 4 countries.
- GBC is granted the patent for “Methods and compositions for treating arteriosclerotic vascular diseases” by European Patent Office.
2020
- GBC’s Antroquinonol receives FDA approval on Covid-19 phase 2 trial in USA.
- GBC completes Antroquinonol phase 2 clinical study – Outperforms Listing Drugs in Relapsed Acute Myeloid Leukemia.
2019
- USA National Institutes of Health (NIH)- National Cancer Institute(NCI) lists the term of drug name: Antroquinonol (HOCENA).
- GBC completes Antroquinonol phase 2 NSCLC clinical study.
- GBC starts phase 2 trial for efficacy of Antroquinonol in AML after Russian MOH approval.
- GBC completes Antroquinonol pre-clinical study for Alzheimer’s disease.
2018
- GBC’s Antroquinonol starts phase 1/2 for Metastatic Pancreatic Cancer as First Line Treatment.
- GBC’s Antroquinonol starts pre-clinical trial for Alzheimer’s disease.
- GBC’s Antroquinonol starts phase 2 for Chronic Hepatitis B treatment.
- GBC is granted the Patent for treating fatty liver diseases by the European Patent Office.
2017
- European Commission has issued the Commission Implementing Decision that Antroquinonol is designated as an orphan medicinal product for the indication of treating pancreatic cancer.
2016
- GBC wins the Advance Queensland – Johnson & Johnson Innovation QuickFire Challenge Award with potential treatment for Alzheimer’s disease.
2015
- GBC is granted 3 orphan drug designations for the treatment of pancreatic cancer , acute myeloid leukemia (AML) and liver cancer by US FDA.
2014
- Antroquinonol acquires patent「Methods and compositions for treating cancer metastasis」, patent No. US 8,648,117 B2.
2013
- GBC’s Antroquinonol completes phase 1 trial and starts phase 2 for NSCLC.
2010
- GBC’s Antroquinonol starts phase 1 trial for NSCLC.
2009
- GBC’s Antroquinonol completes pre-clinical trials for oncology and infectious disease indications.
2006
- Antroquinonol is discovered.